Origene_Jan2021_ProperAntibodyDesignKeeps - 13

Proper Antibody Design Keeps Specificity In Mind

Pasieka / Getty images

receptor. " Potent neutralizing antibodies often

47D11 was shown to bind to cells expressing the

target the receptor interaction site in S1, disabling

full-length spike proteins of both SARS-CoV and

receptor interactions, " the authors continued.

SARS-CoV-2, and potently inhibited viral infection

For their reported antibody discovery effort,

of cultured cells. Tests showed that the antibody

Grosveld and colleagues built on work that the

targeted the S1B receptor-binding domain (RBD)

groups had carried out on antibodies targeting

of the spike proteins of both viruses. The fact that

SARS-CoV, explained co-lead author Berend-Jan

the antibody is cross-reactive indicates that it likely

Bosch, Associate Professor, Research leader

targets the conserved core structure of the S1B RBD,

at Utrecht University. " Using this collection of

the investigators suggested. " Such a neutralizing

SARS-CoV antibodies, we identified an antibody

antibody has potential to alter the course of infec-

that also neutralizes infection of SARS-CoV-2 in

tion in the infected host, support virus clearance or

cultured cells. " The human antibody identified,

protect an uninfected individual that is exposed to

47D11, was generated using Harbour BioMed's

the virus, " Bosch stated.

H2L2 transgenic mouse technology.

Interestingly, the team's results suggested that
GENengnews.com

| 13

http://www.GENengnews.com

Origene_Jan2021_ProperAntibodyDesignKeeps

Table of Contents for the Digital Edition of Origene_Jan2021_ProperAntibodyDesignKeeps